{"created":"2023-06-19T10:29:49.671284+00:00","id":1932,"links":{},"metadata":{"_buckets":{"deposit":"90f12cac-026e-43ce-9e55-7a9ed9d5d871"},"_deposit":{"created_by":31,"id":"1932","owners":[31],"pid":{"revision_id":0,"type":"depid","value":"1932"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00001932","sets":["1709617079800:35:616:623"]},"author_link":["110265","110266","110267","110268","110269","110270","110271","110272","110273","110274","110275","110276","110277","110278","110279","110280","110281","110282","110283","110284","110285","110286","110287","110288"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"87","bibliographicPageStart":"79","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"川崎医学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_33":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"原著論文","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Regular Article","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"川崎医学会","subitem_publisher_language":"ja"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-J44(2)79","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://igakkai.kms-igakkai.com/wp/wp-content/uploads/2018/KMJ-J44(2)79.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00045593","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AN12940574","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-5924","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2758-089X","subitem_source_identifier_type":"EISSN"}]},"item_10001_text_31":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学乳腺甲状腺外科学"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　Fulvestrant has been used for the treatment of postmenopausal patients with advanced or recurrent breast cancer in Japan for over six years. To investigate the utility of fulvestrant, we retrospectively reviewed electronic medical records and evaluated the responses of 51 patients with advanced or recurrent breast cancer treated with fulvestrant alone at the Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital between January 2001 and December 2016. The median age of the subjects was 70 years old. Nine had stage IV diseases and 42 had recurrent diseases. Twenty-three patients had visceral metastases. The median follow-up time after the start of fulvestrant treatment was 18 months. The median number of previous endocrine therapies was 2. Twenty-one patients received chemotherapy previously. Three patients had a complete response, six had a partial response, 25 had a stable disease including 20 patients with a long-term stable disease, and 16 had progressive disease. The objective response rate was 17.6% (9 out of 51), and the clinical benefit rate was 56.9% (29 out of 51). The median progression-free survival (PFS) time was 8 months. The median overall survival (OS) time was 34 months. To investigate predictive factors for response to fulvestrant, subgroup analyses were performed. For liver metastasis, the median PFS and OS time were 9.5 and 41.0 months, respectively, in patients without liver metastasis but 5.0 and 15.0 months, respectively, in those with liver metastasis (P = 0.0386 and P = 0.0036, respectively). For previous chemotherapy, the median PFS and OS time were 12.5 and 41.0 months, respectively, in patients without previous chemotherapy but 3.5 and 24.0 months, respectively, in those with previous chemotherapy (P < 0.0001 and P = 0.0208, respectively). In addition, the Cox’s proportional hazards model revealed that previous chemotherapy was only an independent predictive factor for PFS and that liver metastasis was only an independent predictive factor for worse OS. Although toxicities were recorded in 6 of 51 patients (11.7%), all instances were slight and no patient stopped fulvestrant therapy because of toxicities. In summary, fulvestrant therapy at our hospital provided a 17.6% objective response rate and 56.9% clinical benefit rate in patients with advanced or recurrent breast cancer. These results were similar to those reported previously. According to our subgroup analyses, fulvestrant was unlikely to be effective in patients who received previous chemotherapy or had liver metastasis."}]},"item_10001_textarea_6":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_textarea_language":"ja","subitem_textarea_value":"　ホルモン受容体陽性の閉経後進行・再発乳癌患者に対する内分泌療法として，フルベストラントが本邦で臨床導入されて６年余りが経過した．本剤の有用性を検討するため，2012年１月〜2016年10月に川崎医科大学附属病院乳腺甲状腺外科において，フルベストラントが単独使用され，治療評価が可能であった51症例の電子カルテを後方視的に調査した．対象患者の年齢の中央値は70歳．進行例が９例，再発例が42例．臓器転移ありが23例．観察期間の中央値は18か月．前内分泌療法数の中央値は２．前化学療法歴ありは21例．治療効果は，完全奏効が３例，部分奏効が６例，安定が25 例（うち長期安定は20例），進行が16例であった．客観的奏効は９例（17.6%），臨床的有用は29例（56.9%）であった．無増悪生存（PFS）期間の中央値は８か月，全生存（OS）期間の中央値は34か月であった．治療効果の予測因子を調べるため，サブグループに分けてPFS及びOS を解析した．肝転移の有無では，PFS 期間の中央値は，なしが9.5か月，ありが５か月（P= 0.0386），OS 期間の中央値は，なしが41か月，ありが15か月（P = 0.0036）であった．前化学療法の有無では，PFS 期間の中央値は，なしが12.5か月，ありが3.5か月（P < 0.0001），OS 期間の中央値は，なしが41か月，ありが24か月（P = 0.0208）．多変量解析では，前化学療法歴の有無が唯一のPFS の有意な予測因子であった．また，肝転移の有無が唯一のOS の有意な予測因子であった．有害事象は６例（11.7%）に認めたが，いずれも軽微であり治療が中断されることはなかった．要約すると，ホルモン受容体陽性の進行・再発乳癌の治療薬として，フルベストラントは17.6% の客観的奏効率，56.9% の臨床的有用性が認められ，既知の報告と同等の治療効果であった．フルベストラントは，化学療法歴のある症例，肝転移のある症例では，有用性が低いと考えられた．"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"太田, 裕介","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"紅林, 淳一","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"福間, 佑菜","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岸野, 瑛美","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"川野, 汐織","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"緒方, 良平","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"齋藤, 亙","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小池, 良和","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山下, 哲正","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"野村, 長久","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山本, 裕","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"田中, 克浩","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHTA, Yusuke","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KUREBAYASHI, Junichi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUKUMA, Yuuna","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KISHINO, Emi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KAWANO, Shiori","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OGATA, Ryohei","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SAITOH, Wataru","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOIKE, Yoshikazu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMASHITA, Tetsumasa","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NOMURA, Tsunehisa","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAMOTO, Yutaka","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TANAKA, Katsuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-04-04"}],"displaytype":"detail","filename":"KMJ-J44(2)79.pdf","filesize":[{"value":"1.6 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","objectType":"fulltext","url":"https://kwmed.repo.nii.ac.jp/record/1932/files/KMJ-J44(2)79.pdf"},"version_id":"4b9be6db-af47-4f9c-ae8c-0d6ae48d9201"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"フルベストラント","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"進行・再発乳癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"治療効果","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"有害事象","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"Fulvestrant","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Advanced or recurrent breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Efficacy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Toxicity","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"進行・再発乳癌患者に対するフルベストラントの有用性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"進行・再発乳癌患者に対するフルベストラントの有用性","subitem_title_language":"ja"},{"subitem_title":"Utility of fulvestrant in patients with advanced or recurrent breast cancer","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"31","path":["623"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-04-04"},"publish_date":"2019-04-04","publish_status":"0","recid":"1932","relation_version_is_last":true,"title":["進行・再発乳癌患者に対するフルベストラントの有用性"],"weko_creator_id":"31","weko_shared_id":-1},"updated":"2024-04-13T02:55:04.074406+00:00"}